Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Secured three additional regulatory approvals for world's first chikungunya vaccine, IXCHIQ ® (Canada, Europe, UK); filed adolescent label extension submissions; awarded new $41.3 million grant from ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA decision ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results ...